121 related articles for article (PubMed ID: 35791470)
1. In silico-prediction of chloroquine as a multi-targeted drug against CDKN2A signaling network associated with cutaneous malignant melanoma.
Jan Z; Aqeel M; Munir A; Saeed A; Sadia H; Kalsoom S; Nadeem T; Bashir Z; Awan L; Ud Din S; Muhammad Ali G
Pak J Pharm Sci; 2022 May; 35(3):731-739. PubMed ID: 35791470
[TBL] [Abstract][Full Text] [Related]
2. Genomic rearrangements of the CDKN2A locus are infrequent in Italian malignant melanoma families without evidence of CDKN2A/CDK4 point mutations.
Vignoli M; Scaini MC; Ghiorzo P; Sestini R; Bruno W; Menin C; Gensini F; Piazzini M; Testori A; Manoukian S; Orlando C; D'Andrea E; Bianchi-Scarrà G; Genuardi M
Melanoma Res; 2008 Dec; 18(6):431-7. PubMed ID: 19011513
[TBL] [Abstract][Full Text] [Related]
3. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
4. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas.
Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J
Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Germline BAP1, CDKN2A, and CDK4 Mutations in an Australian Population-Based Sample of Cutaneous Melanoma Cases.
Aoude LG; Gartside M; Johansson P; Palmer JM; Symmons J; Martin NG; Montgomery GW; Hayward NK
Twin Res Hum Genet; 2015 Apr; 18(2):126-33. PubMed ID: 25787093
[TBL] [Abstract][Full Text] [Related]
6. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
7. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations.
Yang XR; Pfeiffer RM; Wheeler W; Yeager M; Chanock S; Tucker MA; Goldstein AM
Int J Cancer; 2009 Dec; 125(12):2912-7. PubMed ID: 19626699
[TBL] [Abstract][Full Text] [Related]
8. Lack of germline PALB2 mutations in melanoma-prone families with CDKN2A mutations and pancreatic cancer.
Yang XR; Jessop L; Myers T; Amundadottir L; Pfeiffer RM; Wheeler W; Pike KM; Yuenger J; Burdett L; Yeager M; Chanock SJ; Tucker MA; Goldstein AM
Fam Cancer; 2011 Sep; 10(3):545-8. PubMed ID: 21614589
[TBL] [Abstract][Full Text] [Related]
9. CDKN2A and CDK4 variants in Latvian melanoma patients: analysis of a clinic-based population.
Pjanova D; Engele L; Randerson-Moor JA; Harland M; Bishop DT; Newton Bishop JA; Taylor C; Debniak T; Lubinski J; Kleina R; Heisele O
Melanoma Res; 2007 Jun; 17(3):185-91. PubMed ID: 17505264
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A variants in a population-based sample of Queensland families with melanoma.
Aitken J; Welch J; Duffy D; Milligan A; Green A; Martin N; Hayward N
J Natl Cancer Inst; 1999 Mar; 91(5):446-52. PubMed ID: 10070944
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation.
Della Torre G; Pasini B; Frigerio S; Donghi R; Rovini D; Delia D; Peters G; Huot TJ; Bianchi-Scarra G; Lantieri F; Rodolfo M; Parmiani G; Pierotti MA
Br J Cancer; 2001 Sep; 85(6):836-44. PubMed ID: 11556834
[TBL] [Abstract][Full Text] [Related]
12. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma.
Berg P; Wennberg AM; Tuominen R; Sander B; Rozell BL; Platz A; Hansson J
Melanoma Res; 2004 Aug; 14(4):251-5. PubMed ID: 15305154
[TBL] [Abstract][Full Text] [Related]
13. Familial melanoma: clinical factors associated with germline CDKN2A mutations according to the number of patients affected by melanoma in a family.
Maubec E; Chaudru V; Mohamdi H; Blondel C; Margaritte-Jeannin P; Forget S; Corda E; Boitier F; Dalle S; Vabres P; Perrot JL; Lyonnet DS; Zattara H; Mansard S; Grange F; Leccia MT; Vincent-Fetita L; Martin L; Crickx B; Joly P; Thomas L; ; Bressac-de Paillerets B; Avril MF; Demenais F
J Am Acad Dermatol; 2012 Dec; 67(6):1257-64. PubMed ID: 22841127
[TBL] [Abstract][Full Text] [Related]
14. The genetics of cutaneous melanoma.
Pollock PM; Trent JM
Clin Lab Med; 2000 Dec; 20(4):667-90. PubMed ID: 11221509
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A germline mutations in individuals with cutaneous malignant melanoma.
Orlow I; Begg CB; Cotignola J; Roy P; Hummer AJ; Clas BA; Mujumdar U; Canchola R; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Kanetsky PA; Wilcox H; Busam K; From L; Berwick M;
J Invest Dermatol; 2007 May; 127(5):1234-43. PubMed ID: 17218939
[TBL] [Abstract][Full Text] [Related]
16. Germline CDKN2A mutations among Greek patients with early-onset and multiple primary cutaneous melanoma.
Stratigos AJ; Yang G; Dimisianos R; Nicolaou V; Stefanaki I; Katsambas AD; Tsao H
J Invest Dermatol; 2006 Feb; 126(2):399-401. PubMed ID: 16374456
[TBL] [Abstract][Full Text] [Related]
17. Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas.
Helsing P; Nymoen DA; Ariansen S; Steine SJ; Maehle L; Aamdal S; Langmark F; Loeb M; Akslen LA; Molven A; Andresen PA
Genes Chromosomes Cancer; 2008 Feb; 47(2):175-84. PubMed ID: 18023021
[TBL] [Abstract][Full Text] [Related]
18. Recurrent patterns of dual RB and p53 pathway inactivation in melanoma.
Yang G; Rajadurai A; Tsao H
J Invest Dermatol; 2005 Dec; 125(6):1242-51. PubMed ID: 16354195
[TBL] [Abstract][Full Text] [Related]
19. CDKN2A as a uveal and cutaneous melanoma susceptibility gene.
Kannengiesser C; Avril MF; Spatz A; Laud K; Lenoir GM; Bressac-de-Paillerets B
Genes Chromosomes Cancer; 2003 Nov; 38(3):265-8. PubMed ID: 14506702
[TBL] [Abstract][Full Text] [Related]
20. Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ; Larson AA; Florell SR; Zone JJ; Cannon-Albright LA; Samlowski WE; Leachman SA
J Invest Dermatol; 2006 Mar; 126(3):660-6. PubMed ID: 16397522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
